Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

688 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reactivation of the G1 enhancer landscape underlies core circuitry addiction to SWI/SNF.
Cermakova K, Tao L, Dejmek M, Sala M, Montierth MD, Chan YS, Patel I, Chambers C, Loeza Cabrera M, Hoffman D, Parchem RJ, Wang W, Nencka R, Barbieri E, Hodges HC. Cermakova K, et al. Among authors: barbieri e. Nucleic Acids Res. 2024 Jan 11;52(1):4-21. doi: 10.1093/nar/gkad1081. Nucleic Acids Res. 2024. PMID: 37993417 Free PMC article.
CHAF1A Blocks Neuronal Differentiation and Promotes Neuroblastoma Oncogenesis via Metabolic Reprogramming.
Tao L, Moreno-Smith M, Ibarra-García-Padilla R, Milazzo G, Drolet NA, Hernandez BE, Oh YS, Patel I, Kim JJ, Zorman B, Patel T, Kamal AHM, Zhao Y, Hicks J, Vasudevan SA, Putluri N, Coarfa C, Sumazin P, Perini G, Parchem RJ, Uribe RA, Barbieri E. Tao L, et al. Among authors: barbieri e. Adv Sci (Weinh). 2021 Oct;8(19):e2005047. doi: 10.1002/advs.202005047. Epub 2021 Aug 8. Adv Sci (Weinh). 2021. PMID: 34365742 Free PMC article.
MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma.
Tao L, Mohammad MA, Milazzo G, Moreno-Smith M, Patel TD, Zorman B, Badachhape A, Hernandez BE, Wolf AB, Zeng Z, Foster JH, Aloisi S, Sumazin P, Zu Y, Hicks J, Ghaghada KB, Putluri N, Perini G, Coarfa C, Barbieri E. Tao L, et al. Among authors: barbieri e. Nat Commun. 2022 Jun 28;13(1):3728. doi: 10.1038/s41467-022-31331-2. Nat Commun. 2022. PMID: 35764645 Free PMC article.
p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy.
Moreno-Smith M, Lakoma A, Chen Z, Tao L, Scorsone KA, Schild L, Aviles-Padilla K, Nikzad R, Zhang Y, Chakraborty R, Molenaar JJ, Vasudevan SA, Sheehan V, Kim ES, Paust S, Shohet JM, Barbieri E. Moreno-Smith M, et al. Among authors: barbieri e. Clin Cancer Res. 2017 Nov 1;23(21):6629-6639. doi: 10.1158/1078-0432.CCR-17-0668. Epub 2017 Aug 18. Clin Cancer Res. 2017. PMID: 28821555 Free PMC article.
Restoration of the molecular clock is tumor suppressive in neuroblastoma.
Moreno-Smith M, Milazzo G, Tao L, Fekry B, Zhu B, Mohammad MA, Di Giacomo S, Borkar R, Reddy KRK, Capasso M, Vasudevan SA, Sumazin P, Hicks J, Putluri N, Perini G, Eckel-Mahan K, Burris TP, Barbieri E. Moreno-Smith M, et al. Among authors: barbieri e. Nat Commun. 2021 Jun 28;12(1):4006. doi: 10.1038/s41467-021-24196-4. Nat Commun. 2021. PMID: 34183658 Free PMC article.
MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma.
Agarwal S, Milazzo G, Rajapakshe K, Bernardi R, Chen Z, Barbieri E, Koster J, Perini G, Coarfa C, Shohet JM. Agarwal S, et al. Among authors: barbieri e. Oncotarget. 2018 Apr 17;9(29):20323-20338. doi: 10.18632/oncotarget.24859. eCollection 2018 Apr 17. Oncotarget. 2018. PMID: 29755654 Free PMC article.
A genome-wide search for promoters that respond to increased MYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma.
Shohet JM, Ghosh R, Coarfa C, Ludwig A, Benham AL, Chen Z, Patterson DM, Barbieri E, Mestdagh P, Sikorski DN, Milosavljevic A, Kim ES, Gunaratne PH. Shohet JM, et al. Among authors: barbieri e. Cancer Res. 2011 Jun 1;71(11):3841-51. doi: 10.1158/0008-5472.CAN-10-4391. Epub 2011 Apr 15. Cancer Res. 2011. PMID: 21498633
G-CSF receptor positive neuroblastoma subpopulations are enriched in chemotherapy-resistant or relapsed tumors and are highly tumorigenic.
Hsu DM, Agarwal S, Benham A, Coarfa C, Trahan DN, Chen Z, Stowers PN, Courtney AN, Lakoma A, Barbieri E, Metelitsa LS, Gunaratne P, Kim ES, Shohet JM. Hsu DM, et al. Among authors: barbieri e. Cancer Res. 2013 Jul 1;73(13):4134-46. doi: 10.1158/0008-5472.CAN-12-4056. Epub 2013 May 16. Cancer Res. 2013. PMID: 23687340 Free PMC article.
688 results